Want to see TSE:ADK full AI Analyst Report?
ADK Stock Chart & Stats
C$0.24
C$0.01(4.35%)
At close: 4:00 PM EDT
C$0.24
C$0.01(4.35%)
Day’s Range― - ―
52-Week RangeC$0.18 - C$0.42
Previous CloseN/A
Volume130.25K
Average Volume (3M)342.67K
Market Cap
C$33.11M
Enterprise ValueC$32.59
Total Cash (Recent Filing)C$1.93M
Total Debt (Recent Filing)C$1.40M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding120,412,550
10 Day Avg. Volume531,548
30 Day Avg. Volume342,665
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)43.19
Price to Sales (P/S)453.09
P/FCF Ratio-7.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary AI Retinal Screening Platform (CARA)Diagnos’ CARA platform is a proprietary AI/image-analysis product positioned in clinical screening workflows. A platform model built into screening programs creates durable product differentiation, potential network effects from image data, and the ability to scale software-based services without proportional headcount increases.
Positive Equity And Asset Base In Latest YearRestoring positive equity and maintaining a tangible asset base after periods of negative equity improves financial footing. This reduces immediate insolvency risk, supports negotiations with lenders or partners, and provides a firmer platform for incremental financing or commercial scaling over the next several months.
Platform Commercial Revenue Model Tied To ScreeningsA contractual, usage-driven or subscription model with healthcare providers aligns revenue with screening volume, enabling predictable recurring streams as programs mature. The low marginal cost of software analysis means incremental screenings can lift margins long-term if adoption and retention grow.
Bears Say
Material Revenue Decline And Shrinking ScaleRevenue collapse signals weak commercial traction or lost contracts, eroding scale economics and making it harder to cover fixed R&D and sales costs. Continued shrinkage impairs ability to expand clinical deployments, undermines bargaining power with partners, and lengthens time to sustainable profitability.
Consistent Negative Operating And Free Cash FlowPersistent cash burn forces reliance on external financing or dilutive raises and limits reinvestment capacity. This ongoing funding need increases execution risk, constrains marketing and product iterations, and can accelerate balance-sheet stress if capital markets tighten or investor appetite wanes.
Elevated Leverage And Prior Negative Equity HistoryHigh debt relative to a small equity base reduces financial flexibility and raises refinancing risk. The history of negative equity highlights prior capital strain, which can increase cost of capital, limit strategic options, and magnify the impact of further operational setbacks on solvency and execution.
Diagnos News
ADK FAQ
What was Diagnos’s price range in the past 12 months?
Diagnos lowest stock price was C$0.17 and its highest was C$0.41 in the past 12 months.
What is Diagnos’s market cap?
Diagnos’s market cap is C$33.11M.
When is Diagnos’s upcoming earnings report date?
Diagnos’s upcoming earnings report date is Aug 20, 2026 which is in 15 days.
How were Diagnos’s earnings last quarter?
Diagnos released its earnings results on Jun 11, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Diagnos overvalued?
According to Wall Street analysts Diagnos’s price is currently Overvalued.
Does Diagnos pay dividends?
Diagnos does not currently pay dividends.
What is Diagnos’s EPS estimate?
Diagnos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Diagnos have?
Diagnos has 120,412,550 shares outstanding.
What happened to Diagnos’s price movement after its last earnings report?
Diagnos reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Diagnos?
Currently, no hedge funds are holding shares in TSE:ADK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Diagnos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-34.26%
Trailing 12-Months
Company Description
Diagnos
DIAGNOS Inc. is a technology firm that delivers software-based services across a broad international footprint, encompassing Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A significant portion of its operations focuses on healthcare, where it provides Computer Assisted Retina Analysis (CARA). This advanced web-based platform is designed to support medical professionals in the early detection of diabetic retinopathy. It also empowers eye care specialists by enabling clear visualization of both standard retinal features and any pathological changes. Beyond its healthcare offerings, DIAGNOS Inc. extends its expertise through consulting services, specializing in the fields of data analytics and artificial intelligence (AI). Established in 1998, the company maintains its corporate headquarters in Brossard, Canada.
Technical Analysis
Rocket Doctor AI
―
Comprehensive Healthcare Systems Inc
―
UniDoc Health Corp
―
PanGenomic Health, Inc. Class A
―
DiagnaMed Holdings Corp.
―